Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

XOMA Corp (NASDAQ:XOMA)

0.7736
Delayed Data
As of Aug 03
 +0.043 / +5.89%
Today’s Change
0.72
Today|||52-Week Range
5.95
-78.45%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$86.1M

Company Description

XOMA Corp. discovers and develops innovative antibody-based therapeutics. It combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. The company focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. It is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Servier through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. The company's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators that could have a major effect on the treatment of diabetes. XOMA was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.

Contact Information

XOMA Corp.
2910 Seventh Street
Berkeley California 94710
P:(510) 204-7200
Investor Relations:
(510) 204-7482

Employees

Shareholders

Individual stakeholders4.82%
Mutual fund holders31.77%
Other institutional30.47%

Top Executives

John W. VarianChief Executive Officer & Director
Thomas BurnsChief Financial Officer & Vice President
Patrick J. ScannonDirector, Chief Scientific Officer & EVP
Charles C. WellsVP-Human Resources & Information Technology
Paul D. RubinChief Medical Officer, SVP-Research & Development